Detalles de la búsqueda
1.
A pharmacist based intervention to improve the care of patients with CKD: a pragmatic, randomized, controlled trial.
BMC Nephrol
; 16: 56, 2015 Apr 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-25881226
2.
Patient-Reported Outcomes in Patients With Advanced Urothelial Cancer Who Are Ineligible for Cisplatin and Treated With First-Line Enfortumab Vedotin Alone or With Pembrolizumab.
J Clin Oncol
; 42(12): 1403-1414, 2024 Apr 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-38215355
3.
Health-related quality of life in GALAHAD: A multicenter, open-label, phase 2 study of niraparib for patients with metastatic castration-resistant prostate cancer and DNA-repair gene defects.
J Manag Care Spec Pharm
; 29(7): 758-768, 2023 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-37404070
4.
Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer.
J Clin Oncol
; 41(25): 4107-4117, 2023 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37369081
5.
Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134.
J Clin Oncol
; 41(2): 186-197, 2023 01 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-36166727
6.
Immune-related Adverse Effects Associated with Programmed Death-1 Inhibitor Therapy in the Treatment of Non-Small Cell Lung Cancer: Incidence, Management, and Effect on Outcomes.
Perm J
; 25: 1, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-33635760
Resultados
1 -
6
de 6
1
Próxima >
>>